ERBB2 Mutation Testing in NSCLC: A Pan-European Real-World Evaluation of the Oncomine Precision Assay
Background/Objectives: The non-small-cell lung cancer (NSCLC) therapeutic landscape has undergone a profound transformation with the introduction of multiple personalized treatment options. Mutations in ERBB2 (HER2) have recently emerged as promising novel targets for the treatment of non-squamous NSCLC (nsNSCLC). Accurate, rapid, and efficient molecular profiling is crucial for identifying patients who may benefit from targeted therapies, including HER2-directed agents. Materials and Methods: Here, we aimed to retrospectively assess the performance of the Oncomine™ Precision Assay* (OPA) in combination with the Ion Torrent Genexus™ Integrated Sequencer* (Thermo Fisher Scientific. Waltham, MA, USA) for detecting ERBB2 mutations in nsNSCLC. A total of 108 archived nsNSCLC samples, consisting of biopsies, resections, and cytological specimens, were used to assess concordance with in-house-validated orthogonal tests. Results: The OPA showed high sensitivity and specificity with an overall accuracy of 100% for single-nucleotide variants (SNVs) and insertions and deletions (Indels). SNVs and Indels with allele frequencies as low as 5% were correctly identified across samples with a tumor cell content ranging from 5% to 95%. Additionally, the assay demonstrated high reproducibility across the six participating laboratories. The turnaround time of the OPA was notably shorter compared to traditional orthogonal methods, facilitating rapid molecular report generation. Conclusions: The OPA in combination with the Ion Torrent Genexus™ System allows for highly sensitive and specific detection of relevant ERBB2 mutations. The assay’s streamlined workflow, coupled with its automated data analysis pipeline, enables a fast turnaround time for testing across a range of sample types. This includes samples with reduced tumor cell content and limited available input. This study demonstrates the future potential of using this assay in a clinical setting.
Authors
- Lukas Bubendorf (ORCID: https://orcid.org/0000-0001-5970-1803)
- John Longshore (ORCID: https://orcid.org/0000-0001-6726-9002)
- Olivier Bordone
- Erwin Keller
- Umberto Malapelle (ORCID: https://orcid.org/0000-0003-3211-9957)
- Christophe Bontoux (ORCID: https://orcid.org/0000-0001-5446-6197)
- Peter Johannes Wild (ORCID: https://orcid.org/0000-0002-1017-3744)
- Ricella Souza da Silva (ORCID: https://orcid.org/0000-0002-3860-6660)
- Giancarlo Troncone (ORCID: https://orcid.org/0000-0003-1630-5805)
- Luisella Righi (ORCID: https://orcid.org/0000-0002-8927-204X)
- Caterina De Luca (ORCID: https://orcid.org/0000-0002-6932-763X)
- Luı́s Cirnes (ORCID: https://orcid.org/0000-0002-2348-5878)
- Melanie Demes
- Ilaria Alborelli (ORCID: https://orcid.org/0000-0001-7849-3958)
- Philip M. Jermann (ORCID: https://orcid.org/0000-0002-8836-4946)
- Fernando López‐Ríos (ORCID: https://orcid.org/0000-0001-6813-0395)
- Paul Hofman (ORCID: https://orcid.org/0000-0003-0431-9353)
- Susana Hernández (ORCID: https://orcid.org/0000-0003-0833-1114)
- Fernando Carlos Schmitt (ORCID: https://orcid.org/0000-0003-1006-6946)
Institutions
- Goethe University Frankfurt (DE)
- Wilmington University (US)
- University Hospital of Basel (CH)
- Centre Hospitalier Universitaire de Nice (FR)
- Research Institute Hospital 12 de Octubre (ES)
- Hospital Universitario 12 De Octubre (ES)
- IPO Porto (PT)
- Department of Medical Sciences (BY)
- University Hospital Frankfurt (DE)
- Thermo Fisher Scientific (United States) (US)
- AstraZeneca (United States) (US)
- University of Turin (IT)
- University of Naples Federico II (IT)
Publication Details
- Journal
- Journal of Molecular Pathology
- Published
- 2025-08-14
- DOI
- https://doi.org/10.3390/jmp6030019
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Amylin Pharmaceuticals
- AstraZeneca
- Thermo Scientific